New research has shown how hemoglobin acts as an antioxidant in brain cells, forming a target for neurodegenerative disease ...

The onset of motor neurone disease (MND) left Sarah without a voice and the use of her hands at the age of 34. It was within ...

MTPA's oral therapy Radicava (edaravone) has shown decreased functional decline and improved survival in long-term ALS trials ...

Neurizon Therapeutics has reported positive topline results from an open-label extension study of its lead candidate NUZ-001 ...

The long-term data supports the drug’s progression into the HEALEY ALS Platform trial, with NUZ-001 dosing set to commence in ...

Trapped by the body with a mind all alone, Some flesh for my maker, and blood from the stone. Music has always been a part of ...

Attaching a molecule dubbed KDS12025 to hemoglobin improved the protein's ability to neutralize abberant reactive oxygen species in the brain ...

The ALS therapy ATH-1105 entered the brain and spinal cord at dose-proportional levels in healthy volunteers, and had a good ...

Familial amyotrophic lateral sclerosis (ALS) is an uncommon form of ALS that occurs due to an inherited gene. The disease causes motor neurons to die, which can lead to progressive muscle weakness.

Amyotrophic Lateral Sclerosis or ALS is a progressive neurodegenerative disease that affects nerve cells in the brain and spinal cord. ALS typically causes muscle atrophy, difficulty in breathing ...

• Key Amyotrophic Lateral Sclerosis Pipeline Therapies: ION363, FB418, SRK-015, RNS60, QRL-201, SAR443820, MN-166, VM202, VRG-50635, Zilucoplan, and others.